Over-The-Counter Oral Contraceptive

On July 13, 2023, the U.S. Food and Drug Administration (FDA) approved the nonprescription sale of Opill (norgestrel) tablets, a progestin-only oral contraceptive. This groundbreaking decision marks the first instance of a daily oral contraceptive being made available over the counter in the United States, allowing individuals to purchase this pregnancy prevention method at pharmacies, grocery stores, and online. Opill's effectiveness, when used correctly, surpasses existing nonprescription methods, highlighting its potential to reduce unintended pregnancies and associated health risks. Opill's official launch is anticipated for 2024, with details regarding its availability and pricing to be determined by the manufacturer. SMFM will continue to work with the Free the Pill coalition and other partners to advocate for access to this and all other contraceptive methods.

Additional Resources

FDA Opill information - Safety information for patients and providers

Provider FAQs from Free the Pill

Free the Pill factsheet provides an overview of over-the-counter insurance coverage by state

Free the Pill OTC OCP research summary - Includes links to publications for further reading

ACOG Committee Opinion: Over-the-counter access to hormonal contraception

ACOG Practice Advisory: First Over-the-counter daily contraceptive pill released

US Medical Eligibility Criteria for Contraceptive Use: Progestin-Only Contraceptives

US Selected Practice Recommendations for Contraceptive Use: Progestin-Only Pills

For Patients:

ACOG FAQs Progestin-only hormonal birth control pill

Everything You Need to Know FAQ from Free the Pill